These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 38793122)

  • 1. Two-Year Outcomes for Patients with Non-ST-Elevation Acute Coronary Syndrome Treated with Magmaris and Absorb Bioresorbable Scaffolds in Large-Vessel Lesions.
    Włodarczak A; Rola P; Włodarczak S; Szudrowicz M; Giniewicz K; Łanocha M; Jaroszewska-Pozorska J; Barycki M; Furtan Ł; Kędzierska M; Włodarczak P; Doroszko A; Lesiak M
    J Pers Med; 2024 May; 14(5):. PubMed ID: 38793122
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Outcomes of the two generations of bioresorbable scaffolds (Magmaris vs. Absorb) in acute coronary syndrome in routine clinical practice.
    Rola P; Włodarczak A; Łanocha M; Barycki M; Szudrowicz M; Kulczycki JJ; Jaroszewska-Pozorska J; Gosiewska A; Woźnica K; Lesiak M; Doroszko A
    Cardiol J; 2022 May; 30(6):870-80. PubMed ID: 35621089
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The 1-Year Safety and Efficacy Outcomes of Magmaris, Novel Magnesium Bioresorbable Vascular Scaffolds in Diabetes Mellitus Patients with Acute Coronary Syndrome.
    Włodarczak A; Łanocha M; Szudrowicz M; Barycki M; Gosiewska A; Kulczycki JJ; Lesiak M; Doroszko A; Rola P
    J Clin Med; 2021 Jul; 10(14):. PubMed ID: 34300332
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Early outcome of magnesium bioresorbable scaffold implantation in acute coronary syndrome-the initial report from the Magmaris-ACS registry.
    Wlodarczak A; Lanocha M; Jastrzebski A; Pecherzewski M; Szudrowicz M; Jastrzebski W; Nawrot J; Lesiak M
    Catheter Cardiovasc Interv; 2019 Apr; 93(5):E287-E292. PubMed ID: 30537203
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Magnesium bioresorbable scaffold (Magmaris) versus polymer biodegradable ultrathin drug-eluting stent (Ultimaster) in acute coronary syndrome. Mid-term outcomes (2 years).
    Włodarczak A; Rola P; Włodarczak S; Szudrowicz M; Jaroszewska-Pozorska J; Barycki M; Furtan Ł; Kędzierska M; Doroszko A; Lesiak M
    Postepy Kardiol Interwencyjnej; 2024 Mar; 20(1):67-75. PubMed ID: 38616930
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mid-term safety and efficacy of magnesium bioresorbable vascular scaffolds - magmaris in diabetic population. 2-Years outcome in acute coronary syndrome cohort.
    Włodarczak A; Rola P; Barycki M; Furtan Ł; Łanocha M; Włodarczak S; Szudrowicz M; Kulczycki JJ; Jaroszewska-Pozorska J; Kędzierska M; Giniewicz K; Doroszko A; Lesiak M
    Diab Vasc Dis Res; 2023; 20(4):14791641231188705. PubMed ID: 37439002
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sex Differences in the Clinical Features and Outcomes of Patients with Acute Coronary Syndrome Treated with Two Generations (Absorb and Magmaris) of Bioresorbable Vascular Scaffolds.
    Włodarczak A; Rola P; Szudrowicz M; Łanocha M; Barycki M; Kulczycki JJ; Gosiewska A; Turkiewicz K; Lesiak M; Doroszko A
    J Clin Med; 2021 Aug; 10(17):. PubMed ID: 34501216
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biodegradable Polymer DES (Ultimaster) vs. Magnesium Bioresorbable Scaffold (BRS Magmaris) in Diabetic Population with NSTE-ACS: A One-Year Clinical Outcome of Two Sirolimus-Eluting Stents.
    Rola P; Włodarczak A; Barycki M; Szudrowicz M; Łanocha M; Kulczycki JJ; Turkiewicz K; Woźnica K; Lesiak M; Doroszko A
    J Diabetes Res; 2021; 2021():8636050. PubMed ID: 34859105
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Magnesium versus poly-L-lactic acid bioresorbable scaffolds: in vivo optical coherence tomography comparison of mechanical performance.
    Abellás-Sequeiros RA; Ocaranza-Sanchez R; Galvaõ-Braga C; Marques J; Gonzalez-Juanatey C
    Arch Cardiol Mex; 2020; 90(1):8-15. PubMed ID: 31996867
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mid-term clinical outcomes of ABSORB bioresorbable vascular scaffold implantation in a real-world population: A single-center experience.
    Costopoulos C; Crowson MC; Brown AJ; Braganza DM; Bennett MR; Hoole SP; West NE
    Cardiovasc Revasc Med; 2015 Dec; 16(8):461-4. PubMed ID: 26440767
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Absorb bioresorbable vascular scaffold versus everolimus-eluting metallic stent in ST-segment elevation myocardial infarction: 1-year results of a propensity score matching comparison: the BVS-EXAMINATION Study (bioresorbable vascular scaffold-a clinical evaluation of everolimus eluting coronary stents in the treatment of patients with ST-segment elevation myocardial infarction).
    Brugaletta S; Gori T; Low AF; Tousek P; Pinar E; Gomez-Lara J; Scalone G; Schulz E; Chan MY; Kocka V; Hurtado J; Gomez-Hospital JA; Münzel T; Lee CH; Cequier A; Valdés M; Widimsky P; Serruys PW; Sabaté M
    JACC Cardiovasc Interv; 2015 Jan; 8(1 Pt B):189-197. PubMed ID: 25616924
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Two year efficacy and safety of small versus large ABSORB bioresorbable vascular scaffolds of ≤18 mm device length: A subgroup analysis of the German-Austrian ABSORB RegIstRy (GABI-R).
    Zaczkiewicz M; Wein B; Graf M; Zimmermann O; Kastner J; Wöhrle J; Thomas R; Hamm C; Torzewski J;
    Int J Cardiol Heart Vasc; 2020 Apr; 27():100501. PubMed ID: 32258361
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of an everolimus-eluting bioresorbable scaffold with an everolimus-eluting metallic stent for the treatment of coronary artery stenosis (ABSORB II): a 3 year, randomised, controlled, single-blind, multicentre clinical trial.
    Serruys PW; Chevalier B; Sotomi Y; Cequier A; Carrié D; Piek JJ; Van Boven AJ; Dominici M; Dudek D; McClean D; Helqvist S; Haude M; Reith S; de Sousa Almeida M; Campo G; Iñiguez A; Sabaté M; Windecker S; Onuma Y
    Lancet; 2016 Nov; 388(10059):2479-2491. PubMed ID: 27806897
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Magmaris Resorbable Magnesium Scaffold Versus Conventional Drug-Eluting Stent in ST-Segment Elevation Myocardial Infarction: 1-Year Results of a Propensity-Score-Matching Comparison.
    de Hemptinne Q; Xaplanteris P; Guédès A; Demeure F; Vandeloo B; Dugauquier C; Picard F; Warne DW; Pilgrim T; Iglesias JF; Bennett J
    Cardiovasc Revasc Med; 2022 Oct; 43():28-35. PubMed ID: 35641364
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-Term Outcomes of Absorb Bioresorbable Vascular Scaffold vs. Everolimus-Eluting Metallic Stent　- A Randomized Comparison Through 5 Years in Japan.
    Kozuma K; Tanabe K; Hamazaki Y; Okamura T; Ando J; Ikari Y; Nakagawa Y; Kusano H; Ediebah D; Kimura T;
    Circ J; 2020 Apr; 84(5):733-741. PubMed ID: 32213737
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A bioresorbable everolimus-eluting scaffold versus a metallic everolimus-eluting stent for ischaemic heart disease caused by de-novo native coronary artery lesions (ABSORB II): an interim 1-year analysis of clinical and procedural secondary outcomes from a randomised controlled trial.
    Serruys PW; Chevalier B; Dudek D; Cequier A; Carrié D; Iniguez A; Dominici M; van der Schaaf RJ; Haude M; Wasungu L; Veldhof S; Peng L; Staehr P; Grundeken MJ; Ishibashi Y; Garcia-Garcia HM; Onuma Y
    Lancet; 2015 Jan; 385(9962):43-54. PubMed ID: 25230593
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sustained Safety and Efficacy of Magnesium Reabsorbable Scaffold: 2-Year Follow-Up Analysis From First Magmaris Multicenter Italian Registry.
    Galli S; Troiano S; Palloshi A; Rapetto C; Pisano F; Aprigliano G; Leoncini M; Ravagnani P; Del Maestro M; Montorsi P
    Cardiovasc Revasc Med; 2022 Aug; 41():69-75. PubMed ID: 35256294
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Magnesium Bioresorbable Scaffold (BRS) Magmaris vs Biodegradable Polymer DES Ultimaster in NSTE-ACS Population-12-Month Clinical Outcome.
    Rola P; Włodarczak A; Włodarczak S; Barycki M; Szudrowicz M; Łanocha M; Furtan Ł; Woźnica K; Kulczycki JJ; Jaroszewska-Pozorska J; Kędzierska M; Doroszko A; Lesiak M
    J Interv Cardiol; 2022; 2022():5223317. PubMed ID: 36605917
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of the short- and long-term safety and therapy outcomes of the everolimus-eluting bioresorbable vascular scaffold system in patients with coronary artery stenosis: Rationale and design of the German-Austrian ABSORB RegIstRy (GABI-R).
    Nef H; Wiebe J; Achenbach S; Münzel T; Naber C; Richardt G; Mehilli J; Wöhrle J; Neumann T; Biermann J; Zahn R; Kastner J; Schmermund A; Pfannebecker T; Schneider S; Limbourg T; Hamm CW
    Cardiovasc Revasc Med; 2016; 17(1):34-7. PubMed ID: 26431767
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-Term Performance of the Magmaris Drug-Eluting Bioresorbable Metallic Scaffold in All-Comers Patients' Population.
    Al Nooryani A; Aboushokka W; AlBaba B; Kerfes J; Abudaqa L; Bhatia A; Mansoor A; Nageeb R; Aleksandric S; Beleslin B
    J Clin Med; 2022 Jun; 11(13):. PubMed ID: 35807011
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.